Kaer Biotherapeutics
Pre-clinicalKAER Biotherapeutics Corporation produces AeroPulsR and SUPRAER-Clinic to rapidly administer high doses of aerosol therapeutics to treat life-threatening respiratory disorders in clinical settings of NICU, PICU, ICU, emergency rooms and surgical suites.
Founded
2019
Focus
ImmunologyOncologyAntibodies
About
KAER Biotherapeutics Corporation produces AeroPulsR and SUPRAER-Clinic to rapidly administer high doses of aerosol therapeutics to treat life-threatening respiratory disorders in clinical settings of NICU, PICU, ICU, emergency rooms and surgical suites.
Funding History
2Total raised: $50M
Series A$42MARCH Venture PartnersJan 15, 2022
Seed$8MAtlas VentureMay 15, 2020
Company Info
TypePrivate
Founded2019
LocationSan Diego, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile